Nasus Pharma has initiated a Phase 2 clinical study to compare NS002, an intranasal epinephrine powder formulation, against EpiPen for anaphylaxis treatment. The study will evaluate bioavailability and pharmacokinetics in 50 healthy adults with allergic rhinitis history, with interim results expected in Q1 2026. NS002 has shown faster epinephrine absorption than autoinjectors, offering a potential needle-free solution. Nasus Pharma aims to provide patients with more user-friendly anaphylaxis treatment options. The company’s proprietary powder-based intranasal technology delivers drugs quickly and efficiently, with the potential for faster absorption compared to liquid-based products.

Read more at GlobeNewswire: Nasus Pharma Announces Initiation of Phase 2 Clinical Study